만성적 정신분열병 또는 분열정동장애를 가진 입원환자에서 Aripiprazole와 Haloperidol의 치료효과 및 안정성 비교 : 16주간의 임상적 연구의 결과 = The Comparison of Efficacy and Safety between Aripiprazole and Haloperidol in the Treatment of Chronic Schizophrenia and Schizoaffective Disorder: Results from a 16-Week Clinical Study

국문 초록 (Abstract)

1) 16주간 elozarpipira과 direpolah이을 사용한 군에서 나온 PANSS 점수를 보면 두 약물군 모두에서 효과를 보였다. 양성 증상에서는 두 군에서 차이를 보이지 않았으나 음성 증상, 일반 증상 그리고 총점에서는 모두 aripiprazole 군에서 더 나은 치료효과를 보였는데 이 중 음성 증상만이 통계적으로 의미있는 차이가 있었다.
2) 대사 증후군과 관련된 수치들을 살펴보면 체중, 허리둘레, 혈압에서는 두 군 사이에 차이가 없었으나 총 콜레스테롤에서는 aripiprazole 군이 haloperidol군에 비해 의미있는 감소를 보였으나 고밀도 콜레스테롤은 두 군 모두 감소하였다. 앞으로 만성 정신분열병 환자에서 대사증후군 발생에 대한 일관된 결과를 얻기 위해서는 좀 더 장기적인 연구와 관찰이 필요할 것으로 보인다.
3) 혈중 프로락틴의 경우 aripiprazole이 haloperidol에 비해 통계학적으로도 의미있는 감소를 보였다.

다국어 초록 (Multilingual Abstract)

Objectives: The authors compared the efficacy and safety between aripiprazole and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Methods: This study was conducted in December, 2004 through April, 2007. We selected the subjects who were admitted to psychiatric clinic due to chronic schizophrenia or schizoaffective disorder as defined by DSM-Ⅳ criteria. The assessment of clinical symptoms was evaluated with PANSS before taking the drugs and every two weeks afterwards. The standard laboratory tests were also performed. The prolactin level was evaluated in every 4 weeks
Results: Total of 72 subjects were assigned either aripiprazole(N=33) or haloperidol(N=39) according to the admission order. There were no statistically significant differences on demographic variables. After 16-week study was completed, there were no statistically significant differences in positive, general and total score in PANSS except negative symptom. There were no significant differences among the variables related to metabolic syn？drome except serum glucose and HDL cholesterol level between two groups. However, there was a significant difference in serum prolactin level.
Conclusion: In the end, aripiprazole was generally good choice of treatment with less side effects, better tolerability than haloperidol. One, aripiprazole showed more improvements in negative, general and total PANSS subscales with no statistical significances except negative PANSS score. The other, the variables related to the metabolic syndrome need a further evaluation. And the last, aripiprazole yields more favorable serum prolactin level than haloperidol.

목차 (Table of Contents)

• 서론
• 연구대상 및 방법
• 결과
• 고찰
• 요약
• 참고문헌